Skip to main content
OpenTrials
Completed

NCT Number: NCT03681990

In Vivo Preoperative Skin Preparation Efficacy Study Within a Defined Product Coverage Area

This study evaluates reduction of resident flora produced by the test product within a defined prepped area of skin.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Eurofins Evic Romania/S.C. BIO HIGH TECH S.R.L.

Bucharest, 040256, Romania

About this study

Three different sample sites within a defined prepped area of skin were collected to determine whether reductions in resident flora produced by the test product are consistent.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male subjects of any race who are at least 18 years of age,
  • Subjects must have an area on their back region to accommodate the treatment coverage area,
  • Subjects must be in good general health,
  • Subjects who satisfy all inclusion/exclusion criteria and will voluntarily read and sign the Informed Consent Form,
  • Subjects who have good skin condition on the test sites,
  • Subjects who are willing to report to the study facility approximately 72 hours prior to Screening or Treatment Day for clipping, if needed,
  • Subjects who are willing to avoid showering and tub-bathing within 72 hours prior to Screening and Treatment Days, and
  • Subjects who have Screening Day baseline counts of > 3.00 log10 per cm2 in each of the 3 sample sites (center, mid-peripheral and peripheral) in the treatment area (back region).

Exclusion criteria

  • Participation in another clinical study in the past 30 days, current participation in another clinical study, or previous participation in this study,
  • Has taken antihistamines in the 48 hours prior to Treatment Day,
  • Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin disorders (including acne) on the applicable test areas,
  • A history of skin allergies,
  • A history of skin cancer within 6 inches of the test areas,
  • Known sensitivity to acrylate-, chlorhexidine gluconate-, or alcohol-containing products, or to medical tape, metals, natural rubber latex, vinyl, or skin-marking inks,
  • A medical diagnosis with physical condition that may put the subject at risk, such as a current or recent severe illness, hepatitis, organ transplant, congestive heart disease, or any immunocompromised conditions, such as AIDS (or HIV positive),
  • Any medical condition or use of any medications that, in the opinion of the Investigator, should preclude participation,
  • Topical antimicrobial exposure within 14 days prior to Screening Day and throughout the study. Restrictions include, but are not limited to antimicrobial soaps, medicated shampoos, medicated lotions, antiperspirants/deodorants, perfumes, after shaves, and colognes,
  • Use of systemic or topical antibiotic medications, steroid medications, or any other product known to affect the normal microbial flora of the skin within 14 days prior to Screening Day and throughout the study,
  • Exposure of the test areas to solvents, acids, bases, strong detergents, fabric softener-treated clothing, or other household chemicals within 14 days prior to Screening Day and throughout the study,
  • Swimming in chemically treated pools or bathing in hot tubs, spas, or whirlpools within 14 days prior to Screening Day and throughout the study,
  • Use of tanning beds, hot waxes, or depilatories (in the applicable test areas) within 14 days prior to Screening Day and throughout the study
  • Bathing and showering within 72 hours prior to Screening Day and throughout the study, or
  • Subject has used moisturizers or any topical treatment (e.g. lotion, sunscreen or shaving cream) on the test sites in the 24-hour period prior to Screening Day and Treatment Day participation in the study.

Treatment and study plan

3M CHG/IPA Prep

Drug

Apply topically to intact skin

Other names: CHG 2%/IPA 70%, Chlorhexidine gluconate 2% / Isopropyl alcohol 70%, Chlorhexidine gluconate and Isopropyl alcohol

Primary outcomes

  1. Comparison of Log Change of Skin Flora Relative to Pre-treatment (Baseline) in Each of 3 Sampling Sites at a Defined Post-treatment Sampling Time.

    Time frame: Post-treatment sampling randomized as 10-minute or 13-minute post-product application

    The primary measure of efficacy is change in skin flora log10 CFU/cm^2 in each of the skin sampling sites relative to baseline skin flora log10 CFU/cm^2. Baseline samples must satisfy the greater than or equal to 3.0 in each of the sampling sites, to be used for data analysis.

Other outcomes

  1. Safety Outcome Evaluated by Skin Irritation Assessment

    Time frame: Assessed pre-treatment (baseline) and post-treatment (10 or 13 minutes)

    Skin irritation (dryness, edema, erythema, rash) assessed on the test sites using a 0-3 rating scale: 0 = no reaction, 1 = mild reaction, 2 = moderate reaction, 3 = severe reaction.

Sponsors and collaborators

Lead sponsor

Solventum US LLC

Industry

Collaborators

  • 3M

Registry information

Official study title

Evaluation of Microbial Population Reductions Within a Defined Product Coverage Area

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Sep 24, 2018
Registry last updated
Oct 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.